iRhythm Technologies (IRTC)

• Market cap: $3.41B
• 1 day: 0.23%
• 5 days: 2.86%
• 1 month: 2.11%
• 3 months: -0.79%
• 6 months: 41.07%
• Year to date: 19.51%
• 1 year: -2.45%
• 5 years: 1.18%
• 10 years: 310.33%
• Sector: Healthcare
• Industry: Medical Devices

About: iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Employees: 2,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

22% more capital invested

Capital invested by funds: $2.54B [Q3] → $3.09B (+$551M) [Q4]

0.03% less ownership

Funds ownership: 109.68% [Q3] → 109.66% (-0.03%) [Q4]

6% less funds holding

Funds holding: 238 [Q3] → 223 (-15) [Q4]

12% less repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 81

24% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 51

56% less call options, than puts

Call options by funds: $11.4M | Put options by funds: $25.8M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $104 3% downside
• Avg. target: $128 20% upside
• High target: $145 36% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

Goldman Sachs David Roman 30% 1-year accuracy 6 / 20 met price target	16% upside $124	Neutral Maintained	24 Feb 2025
Truist Securities Richard Newitter 57% 1-year accuracy 29 / 51 met price target	36% upside $145	Buy Maintained	21 Feb 2025
Wells Fargo Nathan Treybeck 0% 1-year accuracy 0 / 3 met price target	3% downside $104	Equal-Weight Maintained	21 Feb 2025
Needham David Saxon 40% 1-year accuracy 26 / 65 met price target	29% upside $138	Buy Maintained	21 Feb 2025